Suppression of Endogenous Glucose Production by Injectable HDV-Insulin Lispro: A Dose Response Study in Human Subjects With Type 1 Diabetes
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 入组人数
- 18
- 主要终点
- Percentage of suppression of endogenous glucose production
研究概览
简要总结
Single-center, double-blind, random-sequence study assessing the HDV dose-response relationship to Endogenous Glucose Production (EGP), Free Fatty Acids (FFA) and Glucose Disposal Rate (GDR) during a euglycemic clamp procedure following overnight stabilization of blood glucose with intravenous insulin (and, if needed intravenous glucose). EGP and GDR will be determined using established radioisotope methodology. The concentration of Hepatic Directed Vesicles (HDV) in the insulin lispro (LIS) infused during the clamp procedure will be varied such that the percentage of HDV-bound LIS will range from 0%, 1%, 10%, and 100%. Each participant will thus undergo four clamp procedures at the four different HDV levels. LIS will be infused at a constant dose (6 mU/m2/min) for each of the four procedures.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Male or female of age 18 to 65 years, inclusive, who:
- •Has at Screening been diagnosed as T1D for at least 12 months; preference will be given to potential participants who currently use continuous subcutaneous insulin infusion (CSII) therapy;
- •Has at Screening C-peptide ≤0.8 ng/mL (single retest allowed);
- •Has at Screening a BMI ≥18.0 kg/m2 and ≤33.0 kg/m2;
- •Has at Screening HbA1c ≥6.5% and ≤8.5 %.
排除标准
- •Has known or suspected allergy to any component of any of the study drugs in this trial;
- •Is, at Screening, pregnant or breast-feeding, or intends to become pregnant at any time during the duration of the study;
- •Has, at Screening, as judged by the Site Investigator, a history or current evidence of any of advance complications of diabetes;
- •Is, at Screening, judged by the Site Investigator to have a current addiction to alcohol or substances of abuse;
- •Is, at Screening, using one or more drugs that may interfere with the interpretation of trial results or are known to cause clinically relevant interference with insulin action, glucose utilization, or recovery from hypoglycemia (e.g., beta blockers, systemic corticosteroids at pharmacologic doses, cancer chemotherapies);
- •Has, within one (1) month prior to Screening, used either oral anti-diabetic medication or noninsulin anti-diabetic injection therapies (e.g. SGLT-2 inhibitors, pramlintide, GLP-1 agonists, etc.);
- •Has, within one (1) month prior to Screening, received any investigational drug;
- •Has, within three (3) months prior to Screening, smoked tobacco or used any smokeless tobacco or nicotine delivery system (inhaled, oral or buccal);
- •Has at Screening, as judged by the Site Investigator, any condition (intrinsic or extrinsic) that could reasonably be expected to interfere with trial participation, confound evaluation of the data, or pose additional risk to adhering to the study protocol. Examples of such conditions include but are not limited to:
- •Clinically significant active disease of the gastrointestinal, cardiovascular, hepatic, neurological, renal, genitourinary, or hematological systems;
- •History of such an illness or disease;
- •Diminished mental capacity, psychological or behavioral dysfunction, unwilling or resistant to protocol requirements, language barriers.
研究组 & 干预措施
HDV-bound Lispro 10%
Subjects will receive insulin lispro with 10% bound HDV
干预措施: HDV-Insulin Lispro (Drug)
HDV-bound Lispro 0%
Subjects will receive insulin lispro with 0% bound HDV
干预措施: HDV-Insulin Lispro (Drug)
HDV-bound Lispro 1%
Subjects will receive insulin lispro with 1% bound HDV
干预措施: HDV-Insulin Lispro (Drug)
HDV-bound Lispro 100%
Subjects will receive insulin lispro with 100% bound HDV
干预措施: HDV-Insulin Lispro (Drug)
结局指标
主要结局
Percentage of suppression of endogenous glucose production
时间窗: 0 through 6 hours
To establish the dose-response relationship between Hepatic-Directed Vesicles (HDV) and endogenous glucose production at a constant dose of insulin lispro (LIS) during euglycemic clamp procedure
次要结局
未报告次要终点
研究者
Jeremy Pettus, MD
Assistant Professor of Medicine
University of California, San Diego